{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T06:20:50Z","timestamp":1781072450119,"version":"3.54.1"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T00:00:00Z","timestamp":1595548800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2020.01110","type":"journal-article","created":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T15:03:35Z","timestamp":1595603015000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Clinical Indications of Recombinant Human Erythropoietin in a Single Center: A 10-Year Retrospective Study"],"prefix":"10.3389","volume":"11","author":[{"given":"Xiao-Zhen","family":"Guan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei-Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Lin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Juan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De-Qing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,7,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1053\/j.seminhematol.2007.04.004","article-title":"Risks and benefits of erythropoiesis-stimulating agents in cancer management","volume":"44","author":"Beutel","year":"2007","journal-title":"Semin. Hematol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1055\/s-2002-33206","article-title":"Recombinant human erythropoietin usage in a large academic medical center","volume":"8","author":"Bilenker","year":"2002","journal-title":"Am. J. Manag. Care"},{"key":"B3","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1093\/jnci\/dji087","article-title":"Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis","volume":"97","author":"Bohlius","year":"2005","journal-title":"J. Natl. Cancer Inst."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/14651858.CD007303.pub2","article-title":"Erythropoietin or Darbepoetin for patients with cancer\u2013meta-analysis based on individual patient data","volume":"2009","author":"Bohlius","year":"2009","journal-title":"Cochrane Database Syst. Rev."},{"key":"B5","doi-asserted-by":"publisher","first-page":"3436","DOI":"10.1182\/blood-2002-07-2332","article-title":"Critical role for PI 3-kinase in the control of erythropoietin-induced erythroid progenitor proliferation","volume":"101","author":"Bouscary","year":"2003","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.bbi.2006.12.008","article-title":"Schwann cells: activated peripheral glia and their role in neuropathic pain","volume":"21","author":"Campana","year":"2007","journal-title":"Brain Behav. Immun."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1200\/JCO.1994.12.5.1058","article-title":"Recombinant human erythropoietin treatment in cisplatin-associated anemia: a randomized, double-blind trial with placebo","volume":"12","author":"Cascinu","year":"1994","journal-title":"J. Clin. Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"S40","DOI":"10.1007\/s00586-004-0754-9","article-title":"Preoperative erythropoietin in spine surgery","volume":"13","author":"Colomina","year":"2004","journal-title":"Eur. Spine J."},{"key":"B9","first-page":"104","article-title":"New indications and Price Adjustment of Erythropoietin in Shenyang Sansheng Pharmaceutical Company","volume":"4","author":"Company","year":"2001","journal-title":"Chin. J. Nephrop."},{"key":"B10","doi-asserted-by":"publisher","first-page":"860","DOI":"10.3760\/cma.j.issn.1001?7097.2018.11.012","article-title":"Consensus of Chinese experts on diagnosis and treatment of Renal anemia, (2018)","volume":"34","year":"2018","journal-title":"Chin. J. Nephrol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.jpba.2018.02.043","article-title":"Comprehensive glycan analysis of twelve recombinant human erythropoietin preparations from manufacturers in China and Japan","volume":"153","author":"Cowper","year":"2018","journal-title":"J. Pharm. BioMed. Anal."},{"key":"B12","first-page":"925","article-title":"consensus of Chinese experts on the treatment of tumor-related anemia by EPO, (2010-2011)","volume":"15","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1097\/ALN.0000000000000321","article-title":"Erythropoietin and protection of renal function in cardiac surgery (the EPRICS Trial)","volume":"121","author":"Dardashti","year":"2014","journal-title":"Anesthesiology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1038\/ki.2012.270","article-title":"Summary of the KDIGO guideline on anemia and comment: reading between the (guide)line(s)","volume":"82","author":"Dr\u00fceke","year":"2012","journal-title":"Kidney Int."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.2119\/molmed.2011.00259","article-title":"Circulating damage marker profiles support a neuroprotective effect of erythropoietin in ischemic stroke patients","volume":"17","author":"Ehrenreich","year":"2011","journal-title":"Mol. Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"62","DOI":"10.2106\/00004623-199601000-00009","article-title":"The effects of recombinant human erythropoietin on perioperative transfusion requirements in patients having a major orthopaedic operation. The American Erythropoietin Study Group","volume":"78","author":"Faris","year":"1996","journal-title":"J. Bone Joint Surg. Am."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1056\/NEJM199005243222103","article-title":"Recombinant human erythropoietin for patients with AIDS treated with zidovudine","volume":"322","author":"Fischl","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1046\/j.1365-2141.1999.01639.x","article-title":"Purification, amplification and characterization of a population of human erythroid progenitors","volume":"106","author":"Freyssinier","year":"1999","journal-title":"Br. J. Haematol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e75568","DOI":"10.1371\/journal.pone.0075568","article-title":"A low-molecular-weight compound K7174 represses hepcidin: possible therapeutic strategy against anemia of chronic disease","volume":"8","author":"Fujiwara","year":"2013","journal-title":"PloS One"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1093\/icvts\/ivs344","article-title":"The effect of intravenous and oral iron administration on perioperative anaemia and transfusion requirements in patients undergoing elective cardiac surgery: a randomized clinical trial","volume":"15","author":"Garrido-Mart\u00edn","year":"2012","journal-title":"Interact. Cardiovasc. Thorac. Surg."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1200\/JCO.1997.15.3.1218","article-title":"Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group","volume":"15","author":"Glaspy","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/j.1432-1033.1995.075_c.x","article-title":"The signal transduction pathway of erythropoietin involves three forms of mitogen-activated protein (MAP) kinase in UT7 erythroleukemia cells","volume":"234","author":"Gobert","year":"1995","journal-title":"Eur. J. Biochem."},{"key":"B23","first-page":"544","article-title":"A safety and efficacy comparison study of two dosing regimens of epoetin alfa in patients undergoing major orthopedic surgery","volume":"25","author":"Goldberg","year":"1996","journal-title":"Am. J. Orthop."},{"key":"B24","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/0140-6736(93)91143-A","article-title":"Effectiveness of perioperative recombinant human erythropoietin in elective hip replacement. Canadian Orthopedic Perioperative Erythropoietin Study Group","volume":"341","year":"1993","journal-title":"Lancet"},{"key":"B25","doi-asserted-by":"publisher","first-page":"739","DOI":"10.7326\/0003-4819-117-9-739","article-title":"Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency virus (HIV) infection and zidovudine therapy. Overview of four clinical trials","volume":"117","author":"Henry","year":"1992","journal-title":"Ann. Intern. Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/313806a0","article-title":"Isolation and characterization of genomic and cDNA clones of human erythropoietin","volume":"313","author":"Jacobs","year":"1985","journal-title":"Nature"},{"key":"B27","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1182\/blood-2014-01-546333","article-title":"Erythropoietin therapy after allogeneic hematopoietic cell transplantation: a prospective, randomized trial","volume":"124","author":"Jaspers","year":"2014","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s10753-015-0268-0","article-title":"Erythropoietin Pretreatment Attenuates Seawater Aspiration-Induced Acute Lung Injury in Rats","volume":"39","author":"Ji","year":"2016","journal-title":"Inflammation"},{"key":"B29","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1182\/blood.V96.3.941","article-title":"A member of Forkhead family transcription factor, FKHRL1, is one of the downstream molecules of phosphatidylinositol 3-kinase-Akt activation pathway in erythropoietin signal transduction","volume":"96","author":"Kashii","year":"2000","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1053\/j.ajkd.2006.03.010","article-title":"KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease","volume":"47","year":"2006","journal-title":"Am. J. Kidney Dis."},{"key":"B31","doi-asserted-by":"publisher","first-page":"3536","DOI":"10.1182\/blood-2014-11-575357","article-title":"Emerging EPO and EPO receptor regulators and signal transducers","volume":"125","author":"Kuhrt","year":"2015","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.brainresbull.2017.01.016","article-title":"Erythropoietin rescues primary rat cortical neurons from pyroptosis and apoptosis via Erk1\/2-Nrf2\/Bach1 signal pathway","volume":"130","author":"Li","year":"2017","journal-title":"Brain Res. Bull."},{"key":"B33","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1016\/j.lfs.2005.09.053","article-title":"Mechanism of the cardioprotection of rhEPO pretreatment on suppressing the inflammatory response in ischemia-reperfusion","volume":"78","author":"Liu","year":"2006","journal-title":"Life Sci."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1159\/000475434","article-title":"Erythropoietin-Derived Peptide Protects Against Acute Lung Injury After Rat Traumatic Brain Injury","volume":"41","author":"Liu","year":"2017","journal-title":"Cell. Physiol. Biochem."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1002\/1097-0142(19951201)76:11<2319::aid-cncr2820761121>3.0.co;2-u","article-title":"Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy","volume":"76","author":"Ludwig","year":"1995","journal-title":"Cancer"},{"key":"B36","first-page":"1","article-title":"Guidelines for Clinical practice of tumor-related anemia(2015-2016)","author":"Ma","year":"2016","journal-title":"Chin. J. Pract. Internal Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1038\/mt.2013.149","article-title":"Vaccinia virus-mediated expression of human erythropoietin in tumors enhances virotherapy and alleviates cancer-related anemia in mice","volume":"21","author":"Nguyen","year":"2013","journal-title":"Mol. Ther."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1200\/JCO.1991.9.11.2021","article-title":"Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients","volume":"9","author":"Platanias","year":"1991","journal-title":"J. Clin. Oncol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/j.leukres.2008.01.018","article-title":"Erythropoietin, the first century","volume":"32","author":"Ribatti","year":"2008","journal-title":"Leuk. Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1007\/s10753-014-0035-7","article-title":"Erythropoietin reduces acute lung injury and multiple organ failure\/dysfunction associated to a scald-burn inflammatory injury in the rat","volume":"38","author":"Rocha","year":"2015","journal-title":"Inflammation"},{"key":"B41","doi-asserted-by":"publisher","first-page":"440","DOI":"10.3969\/j.issn.1671-4091.2007.08.010","article-title":"Expert consensus on rational use of Recombinant Human Erythropoietin in Renal anemia","volume":"6","author":"Society","year":"2007","journal-title":"Chin. J. Blood Purif."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1007\/s11255-013-0581-1","article-title":"Prevalence and related factors of the absence of anemia among Chinese chronic hemodialysis patients: a multicenter cross-sectional study","volume":"46","author":"Wan","year":"2014","journal-title":"Int. Urol Nephrol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.bbrc.2015.02.020","article-title":"Protection of erythropoietin against ischemic neurovascular unit injuries through the effects of connexin43","volume":"458","author":"Zhou","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2020.01110\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T13:47:49Z","timestamp":1595857669000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2020.01110\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,24]]},"references-count":43,"alternative-id":["10.3389\/fphar.2020.01110"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2020.01110","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,24]]},"article-number":"1110"}}